Indlela i-Hepatitis C eyenziwa ngayo

I-Hepatitis C (i-HCV) yonyango ephumelelayo kakhulu ekuphiliseni intsholongwane, kwaye izidakamizwa zitsha ziza kuphucula imeko yabantu abane-cirrhosis obangelwa yi-HCV, nokuba ngaba uphezulu lwangaphambili luhlulekile.

Ngokuqhelekileyo, phakathi kwama-20% kunye no-30% we-HCV izifo zihlanjululwa ngaphandle kokungenelela kwezokwelapha. Kwama-70% ukuya kuma-80%, usulelo luyakwazi ukuqhubela phambili kwiminyaka eminci kwaye lonakalise ubunzima besibindi.

Phantse ama-30% abantu abasulelekileyo abane-HCV bavelisa iziphumo ezinzulu ezifana ne- cirrhosis , umdlavuza wesibindi , okanye ukuphelelwa kwesibindi sokuphela, kwaye ekugqibeleni kufuneka babe nokutsalwa kwesibindi.

Imigaqo

Injongo yonyango lwe-hepatitis C kukukhusela intsholongwane kwindawo ekungabonakali ngayo kwigazi. Xa intsholongwane ihlala ingabonakali ngeemvavanyo zegazi ngexesha elide, oku kuchazwa njengempendulo ye- virologic eqhubekayo (SVR) .

Uphando luye lwabonisa ukuba abantu abane-HCV abanesifo esingapheliyo ne-HVV abanama-SVR kwiiveki ezingama-24 emva kwe-HCV unyango bane-1% ukuya kwi-2% ithuba lokufumana intsholongwane. I-SVR-24 ibalwa njengonyango. Kwabanye abantu abane-HCV abangenayo i-SVR-24 abanamava okuqhubekayo okuqhubekayo kunye nokuguqulwa kwesinye isiqhamo sesibindi esichaphazelekayo.

I-Antivirals yokuSebenza ngokuthe ngqo (DAAs)

Ukusebenzisa i-anti-virus (DAAs) ngokukhawuleza, yile iklasi elitsha leyeza ukufumana amayeza angama-99%, kunye nexesha lokunyanga kweeveki ezili-12, kunye neempembelelo ezincinci kunye nexesha elifutshane.

Ezi zonyango zingasetyenziselwa ukusuleleka kwe-HCV enesifo esingapheliyo, kunye nesifo esiphezulu sesibindi.

I-DAA iyakwazi ukunyanga inani elinyukayo leengxaki ze-genetic HCV, kwaye i-DAA nganye inconywa kuphela kwimimandla ethile.

Ama-DAA alandelayo avunywe yi-FDA kunyango lwe-hepatitis C engapheliyo:

Inani lamachiza amadala, njenge-Incivek kunye neVictrelis, babesethathe umhlala phantsi ngabakhiqizi, kuba bebengasadingeki xa ii-DAA ezintsha zivunyiwe.

Peginterferon kunye neRibavirin

I-Peginterferon , kunye ne- ribavirin , sele ithathwa njengonyango oluqhelekileyo lwe-HCV engenasifo ngaphambi kokuba kuvele ii-DAA.

Akunjalo unyango oluqhelekileyo kwakhona, kodwa bajongwa njengabalulekile kubantu abanezifo eziphambili, kuquka i-cirrhosis, okanye ezinye iindlela ukuba ii-DAA zingasebenzi. Ngokubanzi, ukuphumelela kwe-peginterferon, kunye ne-ribavirin i malunga ne-90%, engekho ephakamileyo njengaleyo i-DAA entsha, ezinye ii-DAA zinconywa ukuba zithathwe nge-ribavirin efanayo okanye unyango lwe-peginterferon.

Phakathi kweempembelelo ze peginterferon kunye ne-ribavirin yimiphumo emibi yeyeza. Imiphumo ibandakanya:

Impendulo kwi-DAA okanye enye inyango ye-anti-virus ichazwa ngale ndlela ilandelayo:

Ukuhlinzwa

I-HCV inokubangela isifo esiqinileyo sesibindi, kwaye sinokuqhubeka isifo sesibindi sokugqibela. Lo ngummo wokusongela ubomi obangela ukuba isibindi sonakaliswe kangangokuba asikwazi ukusebenza ngendlela efanele. Ukunyanga okutyunjelwayo kwisifo sokugqibela sesibindi kubandakanya ukuphathwa ngokuphawulekayo kwaye mhlawumbi ukufakelwa kwesibindi.

Ukunyamekela / Indlela yokuphila

Ukuba unayo i-HCV, kukho izinto ezibalulekileyo ezifunekayo ukuba uzigcine engqondweni njengoko uphila. Ukuqinisekisa ukuba ugwema nayiphi na into enokulimaza isibindi sakho.

I-Medicine eQinisiweyo kunye neyanye

Ezinye iintswelo ze-vitamin ziye zaphawulwa phakathi kwabantu abane-HCV. Ukungaphumeleli kwe-Vitamin ayikwazi ukubangela iHCV, kuba kubangelwa isifo. Ukuhluleka kwesibindi ngokwayo kubangela ukungabikho kwamavithamini athile.

Kuye kwaphakanyiswa ezinye iindlela zokwelapha kwezinye iindlela kwiindawo ezahlukahlukeneyo unyango nolawulo lwe-HCV, kodwa akukho zifundo ezibonisa ukhuseleko lokusebenza. Ngenxa yokuba ezininzi izityalo kunye neivithamini ziqhutyelwa esibindi, ezinye iindlela zonyango ezingenokuba luncedo xa unesibindi sempiliso singabangela ingozi ukuba isibindi sakho singasimpilo. Kubalulekile ukuba uqaphele ngakumbi ukuba sele usebenzisa i-vitamin okanye i-herb supplement, njengoko ungeke ukwazi ukuwenza kwakhona xa unayo i-HCV.

Ezinye izixhaso eziqhelekileyo ezinobungozi xa unesibindi sokuhluleka kwe-HCV:

> Imithombo:

> I-Beig J, i-Orr D, i-Harrison B, iGane E. I-HCV Ukuxothwa kunye neNew Treatment Free IFN Iphucula iProfayili yeMetaboliki Kwi-HCV-ehlobene ne-Liver Transplant Abamukeli. I-Transpl yeBindi. Ngomhla wama-2018 uMar 25. i-doi: 10.1002 / lt.25060. [Epub ngaphambi kokuprinta]

> Buonomo AR, Zappulo E, Scotto R, et al. Ubunzima be-Vitamin D bubangela umngcipheko kwizifo kwizigulane ezichaphazelekayo nge-cirrhosis ezinxulumene ne-HCV. Int J I-Dis Disfect. Ngo-2017 Okthoba; 63: 23-29. i-doi: 10.1016 / j.ijid.2017.07.026. Epub 2017 Aug 10.

> Caicedo LA, Delgado A, Garcia VH, et al. Ukugqithiswa kwesibindi kwi-Hepatitis C-Izigulane ezichaphazelekayo: Iivela ezivela kwiziko lokuThumela eMzantsi Afrika. Ukutshintshwa kwePro. Ngo-2018 Mar; 50 (2): 493-498. i-doi: 10.1016 / j.transproceed.2017.11.046.

> Jing J, Teschke R. Uhlobo lwezonyango lwamaShayina kunye ne-Herb-induced Liver Injury: Ukuqhathaniswa neLiver-incuted LiverInjury. J Clin Uguqule iHepatol. 2018 uMar 28; 6 (1): 57-68. i-doi: 10.14218 / JCTH.2017.00033. Epub 2017 Oktobha 27.

> Nookala AU, uCrismale J, Schiano T, et al. Iimirhumo zokulwa ne-anti-virus ziphephile kwaye zisebenze ekunyanga kwe-hepatitis C kwixesha elifanayo. Ukutshintshwa kwetlini. Ngo-2018 Mar; 32 (3): e13198. i-doi: 10.1111 / ctr.13198. Epub 2018 Feb 1.